References
- 1. A. J. Wein and E. S. Rovner, Definition and epidemiology of overactive bladder, Urology60 (2002) 7–12; DOI: 10.1016/S0090-4295(02)01784-3.
- 2. S. Tyagi, C. A. Thomas, Y. Hayashi and M. B. Chancellor, The overactive bladder: epidemiology and morbidity, Urol. Clin. North Am.33 (2006) 433–438; DOI: 10.1016/j.ucl.2006.06.002.
- 3. H. Hashim and P. Abrams, Drug treatment of overactive bladder: Efficacy, cost and quality-of-life considerations, Drugs64 (2004) 1643–1656; DOI: 10.2165/00003495-200464150-00003.
- 4. F. Haab, L. Stewart and P. Dwyer, Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder, Eur. Urol.45 (2004) 420–429; DOI: 10.1016/j.eururo.2004.01.008.
- 5. P. K. Kiptoo, M. O. Hamad, P. A. Crooks and A. L. Stinchcomb, Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion, J. Control. Release113 (2006) 137–145; DOI: 10.1016/j.jconrel.2006.04.003.
- 6. K. Maman, S. Aballea, J. Nazir, K. Desroziers, M. E. Neine, E. Siddiqui, I. Odeyemi and Z. Hakimi, Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison, Eur. Urol.65 (2014) 755–765; DOI: 10.1016/j.eururo.2013.11.010.
- 7. T. Omotosho and C. C. G. Chen, Update on tolterodine extended-release for treatment of overactive bladder, Open Access J. Urol. (2010) 185–191; DOI: 10.2147/OAJU.S7232.
- 8. P. Rama Rao, M. N. Reddy, S. Ramakrishna and P. V Diwan, Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits, Eur. J. Pharm. Biopharm.56 (2003) 81–85; DOI: 10.1016/S0939-6411(03)00038-9.
- 9. D. Clemett and B. Jarvis, Tolterodine: a review of its use in the treatment of overactive bladder, Drugs Aging18 (2001) 277–304.
- 10. D. Gautam, T. S. Heard, Y. Cui, G. Miller, L. Bloodworth and J. Wess, Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice, Mol. Pharmacol.66 (2004) 260–267; DOI: 10.1124/mol.66.2.260.
- 11. A. Arora, E. Kisak, P. Karande, J. Newsam and S. Mitragotri, Multicomponent chemical enhancer formulations for transdermal drug delivery: more is not always better, J. Control. Release144 (2010) 175–180; DOI: 10.1016/j.jconrel.2010.02.015.
- 12. V. W. Nitti, S. Sanders, D. R. Staskin, R. R. Dmochowski, P. K. Sand, S. MacDiarmid and H. I. Maibach, Transdermal delivery of drugs for urologic applications: Basic principles and applications, Urology67 (2006) 657–664; DOI: 10.1016/j.urology.2005.11.039.
- 13. M. Akhlaq, M. S. Arshad, A. M. Mudassir, A. Hussain, I. Kucuk, R. Haj-Ahmad, M. Rasekh and Z. Ahmad, Formulation and evaluation of anti-rheumatic dexibuprofen transdermal patches: a quality-by-design approach, J. Drug Target.24 (2016) 603–612; DOI: 10.3109/1061186X.2015.1116538.
- 14. L. Zhao, Y. Li, L. Fang, Z. He, X. Liu, L. Wang, Y. Xu and C. Ren, Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation, Int. J. Pharm.374 (2009) 73–81; DOI: 10.1016/j.ijpharm.2009.03.005.
- 15. F. Sun, C. Sui, Y. Zhou, X. Liu, Y. Shi, Y. Wu and Y. Li, Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder, Int. J. Pharm.454 (2013) 532–538; DOI: 10.1016/j.ijpharm.2013.07.041.
- 16. A. H. Elshafeey, A. O. Kamel and M. M. Fathallah, Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies, Pharm. Res.26 (2009) 2446–2453; DOI: 10.1007/s11095-009-9956-5.
- 17. R. Rajabalaya, S. R. David, J. Chellian, G. Xin Yun and S. Chakravarthi, Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder, Drug Deliv.23 (2016) 1578–1587; DOI: 10.3109/10717544.2015.1116027.
- 18. R. Rajabalaya, G. Leen, J. Chellian, S. Chakravarthi and S. David, Tolterodine tartrate proniosomal gel transdermal delivery for overactive bladder, Pharmaceutics8 (2016) 27; DOI: 10.3390/pharmaceutics8030027.
- 19. R. Rajabalaya, S. R. N. David, J. Khanam and A. Nanda, Studies on the effect of plasticizer on in vitro release and ex vivo permeation from Eudragit E 100 based chlorpheniramine maleate matrix type transdermal delivery system, J. Excipients Food Chem.1 (2010) 3–12.
- 20. S. R. N. David, M. S. Hui, C. F. Pin, F. Y. Ci and R. Rajabalaya, Formulation and in vitro evaluation of ethosomes as vesicular carrier for enhanced topical delivery of isotretinoin, Int. J. Drug Deliv.5 (2013) 28–34.
- 21. T. Oki, A. Toma-Okura and S. Yamada, Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion, J. Pharmacol. Exp. Ther.316 (2006) 1137–1145; DOI: 10.1124/jpet.105.094508.
- 22. R. Rajabalaya, S. R. N. David, J. Khanam and A. Nanda, Effect of platicizers on in vitro release and ex vivo permeation of chlorpheniramine maleate from ethyl cellulose polyvinyl pyrrolidone based matrix patches, Farmacia61 (2013) 975–990.
- 23. S. David, R. Rajabalaya and E. Zhia, Development and in vitro evaluation of self-adhesive matrix-type transdermal delivery system of ondansetron hydrochloride, Trop. J. Pharm. Res.14 (2015) 211–218; DOI: 10.4314/tjpr.v14i2.4.
- 24. R. Rajabalaya, J. Khanam and A. Nanda, Design of a matrix patch formulation for long-acting permeation of diclofenac potassium, Asian J. Pharm. Sci.3 (2008) 30–39.
- 25. R. Rajabalaya, T. W. Xian and S. R. N. David, Preparation and evaluation of transdermal drug delivery of ondansetron hydrochloride: effect of vegetable oils as permeation enhancer, Lat. Am. J. Pharm.31 (2012) 1005–1012.
- 26. R. Rajabalaya, H. Q. Choo and S. R. N. David, Development and in vitro evaluation of matrix type transdermal delivery of ondansetron hydrochloride, Int. J. Drug Deliv.4 (2012) 125–133.
- 27. J. Siepmann, F. Lecomte and R. Bodmeier, Diffusion-controlled drug delivery systems: calculation of the required composition to achieve desired release profiles, J. Control. Release60 (1999) 379–389.
- 28. K. Ghosal, A. Chandra, R. Rajabalaya, S. Chakraborty and A. Nanda, Mathematical modeling of drug release profiles for modified hydrophobic HPMC based gels, Pharmazie67 (2012) 147–155; DOI: 10.1691/ph.2012.1014.
- 29. T. Oki, S. Maruyama, Y. Takagi, H. I. Yamamura and S. Yamada, Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice, Eur. J. Pharmacol.529 (2006) 157–163; DOI: 10.1016/j.ejphar.2005.11.004.